Nippon Chemiphar Parts Ways With Ranbaxy; Takes Over Generics Venture
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Nippon Chemiphar Dec. 8 announced a dissolution of its partnership with India's Ranbaxy Laboratories. A generic drug joint venture established by the two will become a Nippon Chemiphar wholly owned subsidiary
You may also be interested in...
Teva-Kowa Accelerates Japanese Generic Expansion With Taisho Acquisition
Teva-Kowa Pharma announced Dec. 24 it will purchase a majority stake in mid-size generic competitor Taisho Pharmaceutical Industries. The acquisition gives the joint venture immediate access to 220 generic products and 50 sales staff
Teva-Kowa Accelerates Japanese Generic Expansion With Taisho Acquisition
Teva-Kowa Pharma announced Dec. 24 it will purchase a majority stake in mid-size generic competitor Taisho Pharmaceutical Industries. The acquisition gives the joint venture immediate access to 220 generic products and 50 sales staff
Pfizer Leaps Into Japanese Generics Foray; Aims For 100 Generic Products By 2011
Pfizer's Established Products Business Unit, a branch in charge of invigorating off-patent drugs and leading generic drug activities, will establish commercial operations in Japan starting Dec. 1